News Headlines

  1. Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results From URIROX-1 Trial And From Study 206

    Allena Pharmaceuticals, Inc. a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced positive topline results from URIROX-1, its first Phase 3 pivotal trial evaluating reloxaliase in patients with enteric hyperoxaluria (EH), as well as additional data from Study 206, its Phase 2 trial evaluating reloxaliase in high-risk patients with EH and advanced chronic kidney disease (CKD).

  2. Penumbra Indigo Aspiration System IDE Trial For Acute Pulmonary Embolism Meets Primary Safety And Efficacy Endpoints

    Penumbra, Inc. a global healthcare company focused on innovative therapies, today announced that the EXTRACT-PE trial successfully met the primary endpoints, demonstrating the safety and efficacy of the Indigo Aspiration System for aspiration mechanical thrombectomy in patients with acute pulmonary embolism (PE).

  3. Kayentis Opens Japanese Subsidiary To Support Growth Of Asia-Pacific Clinical Trials Sector

    Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) solutions for clinical trials, recently announces the opening of a subsidiary in Japan, the world’s third largest pharmaceutical market, where clinical developments have been expanding.

  4. Lupus Foundation Of America Announces Development Of Next Generation Data Platform To Advance Lupus Research

    Recently, the Lupus Foundation of America is excited to announce the development of a next generation data platform supporting the acceleration and advancement of lupus research.

  5. TrialScope Acquires Clinical Trial Connect

    TrialScope, the global leader in transparency and disclosure compliance solutions, has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will join the TrialScope team as Vice President of Patient Engagement.

  6. Global Survey Finds CROs Undergoing Major Changes To Speed Clinical Trials

    Contract research organizations (CROs) are making significant progress in advancing the industrywide move to improve clinical trial performance, according to the Veeva 2019 Unified Clinical Operations Survey: Annual CRO Report, one of the largest-ever surveys of clinical operations professionals globally.

  7. Cesca Therapeutics Forms Joint Venture With HealthBanks Biotech (USA) To Provide Immune Cell Banking And Cell Processing Services

    Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has entered into a definitive joint venture agreement with HealthBanks Biotech (USA) Inc., one of the world's leading stem cell bank networks, to commercialize its proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO).

  8. Halloran Consulting Group Launches Speaker Series To Drive Meaningful Discussions And Share Insights On Medical Advancements In The Life Science Industry

    Halloran Consulting Group, a life science regulatory, quality and clinical consulting firm, recently announced the launch of its Speaker Series, an interactive speaking circuit featuring Halloran’s most experienced strategic thinkers.

  9. CTTI Releases New Recommendations And Resources For Using Real-World Data To Plan Trial Eligibility Criteria And Recruit Participants

    During a public webinar recently, the Clinical Trials Transformation Initiative (CTTI) will release new recommendations and resources on how to use real-world data (RWD) to evaluate trial eligibility criteria and recruit potential research participants.

  10. Spring Bank Announces Interim Top-Line Results From The First Cohort Of The Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy In Chronic Hepatitis B Patients

    Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, recently announced interim top-line results at 12 weeks from the first cohort of the ongoing Phase 2 trial evaluating the safety, efficacy and pharmacodynamics of escalating doses (50mg, 200mg and 400mg) of the investigational compound inarigivir co-administered with Gilead Sciences’ Vemlidy (tenofovir alafenamide 25mg) for the treatment of chronic hepatitis B virus (HBV) infection.